Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 11 , ISSUE 3 ( July, 2007 ) > List of Articles


TNF-alpha inhibitors: Current indications

Rashmi Sharma, Chaman LaL Sharma*

Keywords : Adalimumab, ankylosing spondylitis, etanercept, infliximab, psoriasis, rheumatoid arthritis, tuberculosis

Citation Information : Sharma R, Sharma* CL. TNF-alpha inhibitors: Current indications. Indian J Crit Care Med 2007; 11 (3):139-148.

DOI: 10.4103/0972-5229.35087

License: CC BY-ND 3.0

Published Online: 01-07-2007

Copyright Statement:  Copyright © 2007; Jaypee Brothers Medical Publishers (P) Ltd.


Advances in the DNA hybrid technology led to the development of various biologicals that specifically target TNF-α. There are currently three anti- TNF- α drugs available- etanercept, infliximab and adalimumab. Etanercept is approved by FDA for rheumatoid arthritis (RA) in 2000 followed by its approval for ankylosing spondylitis, psoriasis and psoriatic arthritis. Infliximab and adalimumab are approved by FDA in 2002 for RA. Infliximab is also approved for ankylosing spondylitis, psoriasis, psoriatic arthritis, crohn′s disease and ulcerative colitis and adalimumab for psoriatic arthritis and ankylosing spondylitis. Other conditions like bronchial asthma, diabetes mellitus, malignancies, septic shock, behcet′s disease, bullous dermatitis, neutrophilic dermatitis, toxic epidermal necrolysis, systemic vasculitis, pyoderma gangrenosum, pustular dermatitis, alcoholic hepatitis, cerebral malaria, hemolytic uremic syndrome, pre-eclampsia, allograft rejection, uveitis, otitis media, snakebite, erythema nodosum, myelodysplastic syndromes, graft versus host disease, dermatomyositis and polymyositis are the potential targets for anti-TNF- α therapy. There are resent reports of serious infections like tuberculosis with the use of anti-TNF therapy. In developing country like India these agents should be used with strict pharmaco-vigilance and chemo-prophylaxis for tuberculosis.

PDF Share
  1. Rheumatoid arthritis: New developments in biologic therapy. J Indian Med Assoc 2006;104:327-30.
  2. Biological therapy in Rheumatoid Arthritis: Current status. Indian J Rheumatol 2006;1:13-9.
  3. Food and drug administration (FDA) approval status of biologicals used in Rheumatology. Indian J Rheumatol 2006;1:41.
  4. FDA approvals: Duetact and humira. Medscape family medicine/primary care MedPulse ® release. Available from: [Last accessed on 2006 Aug 9].
  5. Update on the British Society for Rheumatology guidelines for prescribing TNF-a blockers in adults with Rheumatoid Arthritis (update of previous guidelines of April 2001). Rheumatol 2005;44:157-63.
  6. Anti-TNF-a strategy: Present status of this therapeutic paradigm. Indian J Pharmacol 2004;36:10-4.
  7. Pharmacological treatment of ankylosing spondylitis: A systematic review. Drugs 2005;65:2111-27.
  8. Outcomes of a multicentre randomized clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600.
  9. Treatment of active ankylosing spondylitis with infliximab: A randomized controlled multicentre trial. Lancet 2002;359:1187-93.
  10. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003;48:2224-33.
  11. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
  12. The anti-TNF revolution in ankylosing spondylitis. Med J Am 2004;181:529-30.
  13. Anti-TNF strategies in stenosing and fistulizing Crohn′s disease. Int J Colorectal Dis 2005;20:1-8.
  14. Spotlight on infliximab in Crohn disease and rheumatoid arthritis. BioDrugs 2006;20:67-70.
  15. Transcending conventional therapies: The role of biologic and other novel therapies. Inflamm Bowel Dis 2001;1:S9-16.
  16. Tumor necrosis factor-alpha antibody for induction of remission in Crohn′s disease. Cochrane Database Syst Rev 2004;1:CD003574.
  17. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn′s disease and rheumatoid arthritis. Am J Gastroenterol 2004;99:2385-92.
  18. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci 2004;8:231-3.
  19. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: A randomized controlled trial. Gut 2003;52:998-1002.
  20. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11.
  21. Treatment of psoriatic arthritis with TNF alpha-antagonists. J Rheumatol 2003;62:235-9.
  22. TNF-alpha inhibitors and congestive heart failure. Skinmed 2005;4:363-8.
  23. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial. Lancet 2000;356:385-90.
  24. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7.
  25. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-36.
  26. Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol 2006;17:160-9.
  27. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005;52:522-6.
  28. Therapeutic inhibition of tumor necrosis factor- in patients with heart failure: Cooling an inflamed heart. Heart 2003;89:14-8.
  29. Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40.
  30. A prospective trial of infliximab therapy for refractory uveitis, preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903-12.
  31. Afelimomab. Int J Clin Pract 2000;54:190-3.
  32. Tumour Necrosis Factor (TNF) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma. Thorax. Published Online First: 15 September 2005 doi:10.1136/thx.2005.045260 © 2005 by BMJ Publishing Group Ltd and British Thoracic Society: [Last accessed on 2006 Dec 28].
  33. Afelimomab. Int J Clin Pract 2000;54:190-3.
  34. Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned. Crit Care Med 2001;29:S121-5.
  35. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis. Crit Care Med 2006;34:2484-5.
  36. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody Infliximab. Diabetes Care 2005;28:445-7.
  37. New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF- Inhibitors and GLP-1 Receptor agonists. Ann NY Acad Sci 2004;1035:290-315.
  38. Successful treatment of a small cohort of patients with adult onset of Still′s disease with infliximab: First experiences. Ann Rheum Dis 2001;60:iii55-7.
  39. Two year follow up of infliximab therapy in inflammatory arthritis. J Indian Rheumatol Assoc 2005;13:7-8.
  40. Strategy to prevent tuberculosis during anti TNF therapy in juvenile ankylosing- spondylitis with low dose infliximab without loading schedule: A one year open label study of toxicity and efficacy in 15 patients. J Indian Rheumatol Assoc 2005;13:5-6.
  41. Experience with anti-tumor necrosis factor-a therapy in India. APLAR J Rheumatol 2006;9:136.
  42. Chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) in psoriasis. Indian J Dermatol Venereol Leprol 2006;72:133-5.
  43. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments. Rheumatol (Oxford) 2005;44:1205-6.
  44. Infliximab in spondyloarthropathy. Indian J Rheumatol 2006;14:37.
  45. Authors′ reply. Indian J Rheumatol 2006;14:37-8.
  46. TNF blockers and tuberculosis: An Indian concern. Indian J Rheumatol 2006;1:66-71.
  47. Anti-TNF-a therapies: They are all the same (aren′t they?) Rheumatol 2005;44:271-3.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.